GlassScriptPhysician profile
Abha Mishra
NPI 1285668921
$12,029.47
in general payments reported to CMS, 2019-2025
45 companies · $689 in 2025
The $689 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,676 · 2020: $5,544 · 2021: $606 · 2022: $1,155 · 2023: $1,121 · 2024: $1,238 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,048.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,567.49 | 2019-2022 | |
| Abbvie INC. | $1,173.80 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $826.01 | 2019-2025 | |
| Pfizer INC. | $467.00 | 2023-2025 | |
| Horizon Therapeutics Plc | $435.30 | 2022-2023 | Uplizna |
| Ucb, INC. | $372.05 | 2019-2024 | Nayzilam |
| Acadia Pharmaceuticals INC | $275.89 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $252.85 | 2019-2022 | |
| Amgen INC. | $221.45 | 2024-2025 | Uplizna |
| Philips North America LLC | $218.94 | 2019-2024 | (Di7) Home Pi Undivided |
| Celgene Corporation | $204.90 | 2022-2025 | Zeposia |
| Supernus Pharmaceuticals, INC. | $201.79 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $197.83 | 2019-2022 | |
| Genzyme Corporation | $183.77 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $163.30 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abha Mishra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.